Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical GroupBMGL -0.50%17 EV-to-EBITDA is -2.74 as of Jul. 31, 2026. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Basel Medical Group ranks worse than 196463.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Basel Medical Group's enterprise value is $15.42 Mil.
Basel Medical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.62 Mil. Therefore, Basel Medical Group's EV-to-EBITDA for today is -2.74.
The historical rank and industry rank for Basel Medical Group's EV-to-EBITDA or its related term are showing as below:
BMGL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.19 Med: -1.75 Max: 49.52
Current: -2.74
During the past 4 years, the highest EV-to-EBITDA of Basel Medical Group was 49.52. The lowest was -6.19. And the median was -1.75.
BMGL's EV-to-EBITDA is ranked worse than 100% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.01
vs BMGL: -2.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Basel Medical Group (NAS:BMGL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Basel Medical Group's PE Ratio (TTM) for today is calculated as:
Basel Medical Group's share price for today is $5.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basel Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.046.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Basel Medical Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Basel Medical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's EV-to-EBITDA falls into.
Basel Medical Group's current Enterprise Value is $15.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basel Medical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basel Medical Group (BMGL) has a EV-to-EBITDA of -2.74 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Basel Medical Group. According to the industry distribution chart, Basel Medical Group ranks #999999 out of 509 companies in the Healthcare Providers & Services industry.
Is Basel Medical Group's EV-to-EBITDA too high?
Basel Medical Group's current EV-to-EBITDA is -2.74. Based on the distribution chart, Basel Medical Group ranks #999999 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's EV-to-EBITDA compare to BICX and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Basel Medical Group ranks #999999 out of 509 companies for EV-to-EBITDA. This places Basel Medical Group in the lower half of its industry. The industry median EV-to-EBITDA is 11.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.01, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Basel Medical Group. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current EV-to-EBITDA is -2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current EV-to-EBITDA of -2.74. The current EV-to-EBITDA is -2.74. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current EV-to-EBITDA is -2.74 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
